PROGRESSive Withdrawal Esomeprazole and Acid-related Symptoms (PROGRESS)

  • End date
    Dec 25, 2023
  • participants needed
  • sponsor
    Jules Desmeules
Updated on 25 March 2022
gastrointestinal symptoms
esomeprazole 40 mg
proton pump inhibitors
rebound phenomenon


Rebound acid hypersecretion (RAHS), defined as an increase in gastric acid secretion above pre-treatment levels after PPIs therapy is observed within two weeks after withdrawal of treatment and could theoretically lead to acid-related symptoms such as heartburn, acid regurgitation, or dyspepsia that might result in resumption of therapy. A plausible physiologic theory for the rebound phenomenon suggests that long-term, elevated gastric pH caused by blockage of the proton-pumps stimulates compensatory gastrin release. Interestingly, Reimer et al. demonstrated the occurrence of RAHS in healthy volunteers who had received eight weeks of esomperazole. The clinical symptoms occured in a different prevalence compared with placebo treated patients at ten weeks after withdrawal and until the end of the study (twelve weeks). Twenty to twenty-two percent of patients displayed symptoms ten or twelve weeks after having discontinued PPIs while they occured in 1.7-7% of placebo-treated patients. Efforts should be pursued to restrict PPI therapy use to patients likely to benefit from it.

In this context, we propose to investigate the benefit of a progressive decrease in doses of esomeprazole compared to a sudden discontinuation. This is a randomized, double-blind, placebo-controlled trial with 156 patients treated by esomeprazole 40mg since four weeks least, randomized to one week of placebo or one week of esomeprazole 20mg. We want to compare the prevalence of clinical gastrointestinal symptoms between patients with progressive discontinuation (one week of esomeprazole, 20mg, then discontinuation) or those with sudden discontinuation of esomeprazole 40mg.

Condition Stomach Diseases
Treatment Placebo, Esomeprazole: Nexium® 20mg, Astra Zeneca, CYP2C19 phenotypical analysis
Clinical Study IdentifierNCT02476097
SponsorJules Desmeules
Last Modified on25 March 2022


Yes No Not Sure

Inclusion Criteria

Treatment by esomeprazole 40mg since 4 weeks or more
Esomeprazole withdrawal decided by the clinician
Male and female aged 18-90 years
Volunteers to participate to the study
Must understand and read French language
Must be able to give a written informed consent

Exclusion Criteria

Impairment of cognitive status
Current indication to continue PPI treatment
History of erosive and ulcerative esophagitis, Barrett esophagus, Zollinger-Ellison syndrome
Short-term treatment of documented ulcer disease, as part of a combination regimen for Helicobacter pylori (HP) eradication
Prevention of ulcers due to non-steroidal anti-inflammatory drugs
Hepatic impairment (TP<60%)
Hypersensitivity to omeprazole (CYP2C19 activity) or esomeprazole
Current pregnancy or current breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note